Publications by authors named "Guergana Tritchkova"
Article Synopsis
- - Sotorasib, a KRAS p.G12C-inhibitor, was studied in real-world settings for patients with advanced non-small cell lung cancer (NSCLC) who had received prior treatments, revealing a 38.7% objective response rate and a median overall survival of 9.8 months.
- - Data was collected from 163 patients in a compassionate use program, where a significant portion had poor performance status and existing brain metastases, and some required dose reductions or discontinuation.
- - The study found that factors like PD-L1 expression and KEAP1 mutations influenced efficacy, with KEAP1 mutations associated with worse survival outcomes, while other mutations did not significantly affect response or survival.
Background: The detrimental impact of malnutrition and cachexia in cancer patients subjected to surgical resection is well established. However, how systemic and local metabolic alterations in cancer patients impact the serum metabolite signature, thereby leading to cancer-specific differences, is poorly defined. In order to implement metabolomics as a potential tool in clinical diagnostics and disease follow-up, targeted metabolite profiling based on quantitative measurements is essential.
View Article and Find Full Text PDF